Meeting
2023 ASCO Breakthrough
Clinical implications of drug-metabolizing genes CYP3A4 and GSTP1 single nucleotide polymorphisms in oral cancer patients undergoing induction chemotherapy.
Authors
Pranab Kumar Sahoo
Chittaranjan National Cancer Institute, Kolkata, India
Pranab Kumar Sahoo , Tanuma Mistry , SUSHMITA GHOSH , Sutapa Mahata , Sinjini Sarkar , Ranita Pal , Trisha Choudhury , Sriparna Datta , Syamsundar Mandal , Anup Kumar Bhowmick , KALYAN KUSUM MUKHERJEE , Vilas Nasare
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Gastrointestinal Cancer,Gynecologic Cancer,Head and Neck Cancer,Quality of Care,Genetics/Genomics/Multiomics,Healthcare Equity and Access to Care,Healthtech Innovations,Models of Care and Care Delivery,Population Health,Viral-Mediated Malignancies
Sub Track
Other Therapeutic Interventions
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 95)
DOI
10.1200/GO.2023.9.Supplement_1.95
Abstract #
95
Poster Bd #
F1
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Circulating tumor DNA analysis using targeted sequencing of 508 clinically actionable genes in patients with high grade serous ovarian cancer.
First Author: Anniina Färkkilä
Poster
2012 ASCO Annual Meeting
The impact of genetic variability on severe toxicity of (neo-) adjuvant chemotherapy in breast cancer patients receiving 5-fluorouracil, epirubicin, and cyclofosfamide (FEC).
First Author: Christof Vulsteke
Poster
2021 ASCO Quality Care Symposium
Sustainability and clinical outcomes of routine screening for pathogenic DPYD gene variants prior to fluoropyrimidine (FP) chemotherapy for gastrointestinal (GI) cancer.
First Author: Gabriel A. Brooks
Poster
2018 Gastrointestinal Cancers Symposium
Intensive first-line triplet chemotherapy plus cetuximab FIr-C/FOx-C in RAS wild-type MCRC: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.
First Author: Gemma Bruera